## Vanessa M Barnabei

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7013059/publications.pdf

Version: 2024-02-01

39 papers 4,887

394421 19 h-index 36 g-index

39 all docs 39 docs citations

39 times ranked 3702 citing authors

#	Article	IF	CITATIONS
1	Sexual activity and vaginal symptoms in the postintervention phase of the Women's Health Initiative Hormone Therapy Trials. Menopause, 2018, 25, 252-264.	2.0	9
2	Surgical Competency for Robot-Assisted Hysterectomy: Development and Validation of a Robotic Hysterectomy Assessment Score (RHAS). Journal of Minimally Invasive Gynecology, 2017, 24, 55-61.	0.6	20
3	The impact of birth weight on cardiovascular disease risk in the Women's Health Initiative. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 239-245.	2.6	76
4	In Reply. Obstetrics and Gynecology, 2015, 126, 214-215.	2.4	0
5	Incidence of endometrial spotting or bleeding during continuous-combined estrogen-progestin therapy in postmenopausal women with and without hypertension. Menopause, 2015, 22, 1067-1075.	2.0	6
6	Prophylactic Use of Negative Pressure Wound Therapy After Cesarean Delivery. Obstetrics and Gynecology, 2015, 125, 299-307.	2.4	41
7	Association of Serum 17βâ€Estradiol Concentration, Hormone Therapy, and Alveolar Crest Height in Postmenopausal Women. Journal of Periodontology, 2015, 86, 595-605.	3.4	13
8	Autism and induced labor: is calcium a potential mechanistic link?. American Journal of Obstetrics and Gynecology, 2014, 210, 494-495.	1.3	4
9	Patterns and predictors of sexual activity among women in the Hormone Therapy trials of the Women's Health Initiative. Menopause, 2011, 18, 1160-1171.	2.0	76
10	Increased incident hip fractures in postmenopausal women with moderate to severe pelvic organ prolapse. Menopause, 2011, 18, 967-973.	2.0	11
11	Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial. Menopause, 2010, 17, 946-954.	2.0	61
12	Relation of demographic factors, menstrual history, reproduction and medication use to sex hormone levels in postmenopausal women. Breast Cancer Research and Treatment, 2008, 108, 217-231.	2.5	40
13	The Effects of a Web-Based Tool on Patient-Provider Communication and Satisfaction with Hormone Therapy: A Randomized Evaluation. Journal of Women's Health, 2008, 17, 147-158.	3.3	15
14	Association of pelvic organ prolapse and fractures in postmenopausal women. Menopause, 2008, 15, 59-66.	2.0	34
15	Hormone Therapy in Menopause. , 2008, , 436-440.		0
16	Perimenopause., 2008,, 647-649.		0
17	Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause. JAMA - Journal of the American Medical Association, 2007, 297, 1465-77.	7.4	1,443
18	Hormone Therapy and Cardiovascular Risk—Reply. JAMA - Journal of the American Medical Association, 2007, 298, 623.	7.4	1

#	Article	IF	CITATIONS
19	Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause. Obstetrical and Gynecological Survey, 2007, 62, 522-523.	0.4	1
20	Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus. Archives of Internal Medicine, 2006, 166, 772.	3.8	195
21	Menopausal Symptoms and Treatment-Related Effects of Estrogen and Progestin in the Women $\hat{E}^{1}/4$ s Health Initiative. Obstetrics and Gynecology, 2005, 105, 1063-1073.	2.4	249
22	Symptom Experience After Discontinuing Use of Estrogen Plus Progestin. Obstetrical and Gynecological Survey, 2005, 60, 804-806.	0.4	1
23	Symptom Experience After Discontinuing Use of Estrogen Plus Progestin. JAMA - Journal of the American Medical Association, 2005, 294, 183.	7.4	153
24	Effects of Estrogen With and Without Progestin on Urinary Incontinence. JAMA - Journal of the American Medical Association, 2005, 293, 935.	7.4	429
25	Is There an Association between Athletic Amenorrhea and Endothelial Cell Dysfunction?. Medicine and Science in Sports and Exercise, 2003, 35, 377-383.	0.4	83
26	Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstetrics and Gynecology, 2002, 100, 1209-1218.	2.4	136
27	Pelvic organ prolapse in the women's health initiative: Gravity and gravidity. American Journal of Obstetrics and Gynecology, 2002, 186, 1160-1166.	1.3	1,024
28	Personal digital assistant for "real time―assessment of women's health in the clinical years. American Journal of Obstetrics and Gynecology, 2002, 187, S19-S21.	1.3	10
29	A longitudinal women's health curriculum: A multi-method, multiperspective needs assessment. American Journal of Obstetrics and Gynecology, 2002, 187, S12-S14.	1.3	10
30	Plasma Homocysteine in Women Taking Hormone Replacement Therapy: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. Journal of Women's Health and Gender-Based Medicine, 1999, 8, 1167-1172.	1.5	44
31	Symptom relief and side effects of postmenopausal hormones: results from the postmenopausal estrogen/progestin interventions trial. Obstetrics and Gynecology, 1998, 92, 982-988.	2.4	204
32	Transvaginal Ultrasonography Compared with Endometrial Biopsy for the Detection of Endometrial Disease. New England Journal of Medicine, 1997, 337, 1792-1798.	27.0	225
33	Enhanced twin pregnancy detection within an open neural tube defect and down syndrome screening protocol using free-beta hCG and AFP. Prenatal Diagnosis, 1995, 15, 1131-1134.	2.3	15
34	Advent of Maternal Serum Markers for Down Syndrome Screening. Obstetrical and Gynecological Survey, 1995, 50, 316-320.	0.4	14
35	Isodicentric X Chromosome in a Girl With Gonadal Dysgenesis. Southern Medical Journal, 1983, 76, 249-250.	0.7	5
36	Epsteinâ€Barr Virus in Normal Pregnant Women*. American Journal of Reproductive Immunology: AJRI: Official Journal of the American Society for the Immunology of Reproduction and the International Coordination Committee for Immunology of Reproduction, 1982, 2, 217-221.	1.1	25

3

#	Article	IF	CITATIONS
37	Chromosomal breakage and sister chromatid exchange in peripheral blood lymphocytes and lymphoblastoid cell lines in the X-linked lymphoproliferative syndrome. Cancer Genetics and Cytogenetics, 1982, 6, 313-321.	1.0	10
38	Epstein-Barr virus-induced diseases in boys with the X-linked lymphoproliferative syndrome (XLP). American Journal of Medicine, 1982, 73, 49-56.	1.5	197
39	Bloom syndrome fibroblasts secrete a metabolite which enhances SCE rate in normal fibroblasts. American Journal of Medical Genetics Part A, 1982, 12, 245-245.	2.4	7